Literature DB >> 7593556

Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta.

S Issazadeh1, A Ljungdahl, B Höjeberg, M Mustafa, T Olsson.   

Abstract

The kinetics of mRNA expression in the central nervous system (CNS) for a series of putatively disease-promoting and disease-limiting cytokines during the course of experimental autoimmune encephalomyelitis (EAE) in Lewis rats were studied. Cytokine mRNA-expressing cells were detected in cryosections of spinal cords using in situ hybridization technique with synthetic oligonucleotide probes. Three stages of cytokine mRNA expression could be distinguished: (i) interleukin (IL)-12, tumor necrosis factor (TNF)-beta (= lymphotoxin-alpha) and cytolysin appeared early and before onset of clinical signs of EAE; (ii) TNF-alpha peaked at height of clinical signs of EAE; (iii) IL-10 appeared increasingly at and after clinical recovery. The early expression of IL-12 prior to the expression of interferon-gamma (IFN-gamma) mRNA shown previously is consistent with a role of IL-12 in promoting proliferation and activation of T helper 1 (Th1) type cells producing IFN-gamma. The TNF-beta mRNA expression prior to onset of clinical signs favours a role for this cytokine in disease initiation. A pathogenic effector role of TNF-alpha was suggested from these observations that TNF-alpha mRNA expression roughly paralleled the clinical signs of EAE. This may be the case also for cytolysin. IL-10-expressing cells gradually increased to high levels in the recovery phase of EAE, consistent with a function in down-regulating the CNS inflammation. From these data we conclude that there is an ordered appearance of putative disease-promoting and -limiting cytokines in the CNS during acute monophasic EAE.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593556     DOI: 10.1016/0165-5728(95)00100-g

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  32 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; C Benou; A D Salama; M J Grusby; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

3.  Modulation of the expression of integrins on glial cells during experimental autoimmune encephalomyelitis. A central role for TNF-alpha.

Authors:  S C Previtali; J J Archelos; H P Hartung
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

4.  Borna disease virus accelerates inflammation and disease associated with transgenic expression of interleukin-12 in the central nervous system.

Authors:  Susanna Freude; Jürgen Hausmann; Markus Hofer; Ngan Pham-Mitchell; Iain L Campbell; Peter Staeheli; Axel Pagenstecher
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis.

Authors:  G C Suvannavejh; M C Dal Canto; L A Matis; S D Miller
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

6.  Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat.

Authors:  T Smith; A K Hewson; C I Kingsley; J P Leonard; M L Cuzner
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

7.  Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by altering balance among CD4+ T-cell subsets.

Authors:  Junpeng Wang; Zhihong Ren; Yanmei Xu; Sheng Xiao; Simin N Meydani; Dayong Wu
Journal:  Am J Pathol       Date:  2011-11-03       Impact factor: 4.307

8.  Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis.

Authors:  Nicole Trager; Amena Smith; Gerald Wallace Iv; Mitsuyoshi Azuma; Jun Inoue; Craig Beeson; Azizul Haque; Naren L Banik
Journal:  J Neurochem       Date:  2014-02-12       Impact factor: 5.372

9.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.

Authors:  M Comabella; K Balashov; S Issazadeh; D Smith; H L Weiner; S J Khoury
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

10.  A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis.

Authors:  Yongmei Wang; J T Evans; Frederick Rodriguez; Patrick Fields; Cynthia Mueller; Tanuja Chitnis; Samia J Khoury; Margaret S Bynoe
Journal:  J Neuroimmunol       Date:  2008-12-18       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.